Oxford BioTherapeutics Licenses Lonza’s GS Gene Expression System

September 02,2011 Oxford, United Kingdom and Basel, Switzerland

Oxford BioTherapeutics Ltd (OBT) and Lonza announced today a non-exclusive license agreement providing OBT with access to Lonza’s GS Gene Expression System™. The agreement covers the research, development and commercial use of the GS System™ by OBT and contains standard payments and license fees which have not been disclosed.

Licensing of the GS Gene Expression System™ expands OBT’s access to world-class technologies for its maturing pipeline of therapeutic antibodies in oncology, and demonstrates its commitment to strengthening both antibody production and preclinical capabilities.

“We are delighted to have access to Lonza’s GS Gene Expression SystemTM as an addition to our technology portfolio“, commented Tom Boone, who recently joined OBT as Senior Vice President, Protein Sciences following 28 years at Amgen. “The speed and ease of use of the GS System™ will aid the rapid selection of high-producing cell lines and accelerate the production and development of our most promising anticancer agents. “

“We are proud to have our GS Gene Expression System™ contribute to Oxford BioTherapeutics innovation in cancer research,” said Janet White, Head of Development Services. “We look forward to supporting OBT’s efforts to expand and develop its pipeline of promising new oncology drugs.”

OBT has a broad pipeline of preclinical antibody programs directed to novel cancer targets that it has identified using its OGAP® proteomic database.

 

About Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is a leading international biotechnology company focused on the development and commercialization of innovative antibody-based cancer medicines, with integrated diagnostics, against novel targets that it has discovered in its unique OGAP® proteomic database. OBT accesses leading antibody technologies and expertise through its partnerships with many of the world leaders in antibody development, including the BMS (Medarex) HuMAb platform, the Amgen (Abgenix) XenomouseTM platform, the transgenic phage technology of Alere (formerly Biosite) and the POTELLIGENT® Technology of BioWa, and through its development alliances with GSK and sanofi-aventis. OBT’s diagnostic collaboration with Alere also provides the opportunity to develop tailored diagnostics for OBT’s therapeutic products. These partnerships have enabled OBT to use its unique position to convert its novel oncology targets into a highly attractive pipeline of therapeutic antibodies. OBT’s pipeline will deliver innovative and cost-effective first-in-class medicines to fulfill major unmet patient needs in the field of cancer.

For further information, please see www.OxfordBioTherapeutics.com

 

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bio-products which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.

 

About the GS Gene Expression System™

The GS Gene Expression System™, which is owned and licensed by Lonza, is used for the production of therapeutic recombinant proteins and monoclonal antibodies. Nearly 100 biotechnology and pharmaceutical companies and over 75 academic laboratories worldwide are successfully using the GS Gene Expression System™ which has established itself as the industry standard. This system is characterized by its speed and ease of use. In addition, the higher yielding cell lines provide cost-efficient production of therapeutic proteins.

 

About OGAP®

The Oxford Genome Anatomy Project (OGAP®) database represents the world’s largest proprietary collection of disease-associated proteins. OGAP® oncology contains proteomic data on 5,000 cancer membrane proteins combined with their genomic and clinical information derived from human blood and cancer tissue studies. OGAP® contains proprietary target information on three quarters of the entire human proteome. Over one million human protein fragments have been sequenced in OGAP in 50 different human tissues representing 60 diseases including 25 forms of cancer covering 17,000 different genes and over three quarters of all human proteins and genetic variants in over eight million SNPs and haplotypes.

OGAP® is a registered trade mark of Oxford BioTherapeutics Ltd.

 

Further information

Lonza Group Ltd
Head of Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com

Lonza Group Ltd
Media Relations
Melanie Disa
Tel +1 201 316 9413
Fax +1 201 696 3533
melanie.disa@lonza.com

 

Oxford BioTherapeutics Enquiries

Chief Executive Officer
Christian Rohlff, Ph.D
Tel +44(0) 1235 861770
cr@oxbt.co.uk

Media Enquiries/Citigate
David Dible
Tel +44 (0) 207 6389571
david.dible@citigatedr.co.uk

Browse All News
Bg